Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street Analyst
On Monday, Keybanc analyst Scott Schoenhaus revised his price target on Recursion Pharmaceuticals (NASDAQ: RXRX) upward, opining the stock would climb by 33% and hit $16. The call came days after the rare-disease drug developer reported 2023 fourth-quarter earnings, which caused the market to dump its shares to the tune of 13%.
Here's what Shoenhaus could be thinking will catalyze a reversal for this stock.
In January, Recursion made an interesting decision regarding one of the assets it's developing in its fibrotic disease collaboration with .
Source Fool.com
Bayer AG Stock
€27.75
-3.310%
Currently there is a rather positive sentiment for Bayer AG with 16 Buy predictions and 7 Sell predictions.
As a result the target price of 45 € shows a very positive potential of 62.19% compared to the current price of 27.75 € for Bayer AG.
